A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer

Taussky, Daniel; Soulières, Denis; Azoulay, Laurent; Yin, Hui; Bahig, Houda; Bahary, Jean-Paul; Delouya, Guila

doi:10.1007/s11523-017-0516-3

Cited by 7 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to now, leukocytes detected in the CellSearch cartridges were considered to constitute a non-specific carryover. The weak correlation between the leukocyte counts in the EpCAM-enriched samples and the leukocyte counts from the available complete blood counts (Table S1) rejects a plausible explanation that the leukocyte carryover reflects the total leukocyte count of patients, with the latter known to be associated with patients' clinical outcome in bladder, prostate, and non-small-cell lung cancers [44][45][46][47], as well as in colorectal cancer ( Table 1). That observation raised questions about the subtype of leukocytes isolated with the CTC kit, which either overexpress Fcγ receptors that bind to the IgG immunoglobulins of the anti-EpCAM ferrofluid, or express EpCAM.…”

Section: Discussionmentioning

confidence: 95%

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer

Nanou

Mol

Coumans

et al. 2020

Cells

View full text Add to dashboard Cite

Elevated, tumor-derived extracellular vesicle (tdEV) and circulating tumor cell (CTC) loads in metastatic cancer are associated with poor clinical outcome. Herein, we investigate whether endothelium-derived extracellular vesicles (edEVs) can be detected in the blood of metastatic colorectal cancer (mCRC) patients, and whether those vesicles associate with prognosis. The open-source ACCEPT (Automated CTC Classification, Enumeration, and Phenotyping) software was used to enumerate edEVs, tdEVs, and other objects from digitally stored CellSearch images acquired after CTC and circulating endothelial cell (CEC) enrichment from the blood of 395 mCRC patients before the initiation of a new therapy. Patients had participated in the prospective phase III CAIRO2 study. The presence of edEVs was found 5- to 10-fold higher than CECs. The hazard ratio (HR) (95% CI) of progression-free survival (PFS) for increased CTCs (≥3 in 7.5 mL), tdEVs (≥40 in 7.5 mL), and edEVs (≥287 in 4.0 mL.) was 1.4 (1.1–1.9), 2.0 (1.5–2.6), and 1.7 (1.2–2.5), respectively. The HR of Overall Survival (OS) for increased CTCs, tdEVs and edEVs was 2.2 (1.7–3.0), 2.7 (2.0–3.5), and 2.1 (1.5–2.8), respectively. There was no cut-off value for CECs, leading to a dichotomization of patients with a significant HR. Only tdEVs remained a significant predictor of OS in the final multivariable model.

show abstract

Section: Discussionmentioning

confidence: 95%

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer

Nanou

Mol

Coumans

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…A systematic review by Claps and colleagues [ 45 ] investigated the association between total testosterone and overall mortality (including prostate cancer-specific mortality). In their meta-analysis of four cohort studies [ 38 , 39 , 46 , 47 ], the authors found little evidence of an association of total testosterone with overall mortality (HR = 1.03, 95% CI = 0.99–1.08, p = 0.19). Two of these cohort studies were not included our review as one study reported on men treated with ADT [ 46 ] and the other study reported on overall survival [ 47 ], not prostate cancer-specific survival.…”

Section: Discussionmentioning

confidence: 99%

“…In their meta-analysis of four cohort studies [ 38 , 39 , 46 , 47 ], the authors found little evidence of an association of total testosterone with overall mortality (HR = 1.03, 95% CI = 0.99–1.08, p = 0.19). Two of these cohort studies were not included our review as one study reported on men treated with ADT [ 46 ] and the other study reported on overall survival [ 47 ], not prostate cancer-specific survival. It is, therefore, evident that further research would benefit from examining testosterone concentrations in relation to prostate cancer-specific mortality as well as on measures of advanced prostate cancer (i.e., Gleason scores of ≥ 8, development of metastasises).…”

Section: Discussionmentioning

confidence: 99%

Does testosterone mediate the relationship between vitamin D and prostate cancer progression? A systematic review and meta-analysis

Robles

Harrison

Tan

et al. 2022

Cancer Causes Control

View full text Add to dashboard Cite

Purpose Observational studies and randomized controlled trials (RCTs) have shown an association between vitamin D levels and prostate cancer progression. However, evidence of direct causality is sparse and studies have not examined biological mechanisms, which can provide information on plausibility and strengthen the evidence for causality. Methods We used the World Cancer Research Fund International/University of Bristol two-stage framework for mechanistic systematic reviews. In stage one, both text mining of published literature and expert opinion identified testosterone as a plausible biological mechanism. In stage two, we performed a systematic review and meta-analysis to assess the evidence from both human and animal studies examining the effect of vitamin D on testosterone, and testosterone on advanced prostate cancer (diagnostic Gleason score of ≥ 8, development of metastasis) or prostate cancer-specific mortality. Results A meta-analysis of ten human RCTs showed evidence of an effect of vitamin D on total testosterone (standardised mean difference (SMD) = 0.133, 95% CI = − 0.003–0.269, I2 = 0.0%, p = 0.056). Five human RCTs showed evidence of an effect of vitamin D on free testosterone (SMD = 0.173, 95% CI = − 0.104–0.450, I2 = 52.4%, p = 0.220). Three human cohort studies of testosterone on advanced prostate cancer or prostate cancer-specific mortality provided inconsistent results. In one study, higher levels of calculated free testosterone were positively associated with advanced prostate cancer or prostate cancer-specific mortality. In contrast, higher levels of dihydrotestosterone were associated with lowering prostate cancer-specific mortality in another study. No animal studies met the study eligibility criteria. Conclusion There is some evidence that vitamin D increases levels of total and free testosterone, although the effect of testosterone levels within the normal range on prostate cancer progression is unclear. The role of testosterone as a mechanism between vitamin D and prostate cancer progression remains inconclusive.

show abstract

“…We found that the number of neutrophils, and not the NLR, was an independent prognostic factor for overall survival [ 13 ]. In a follow-up study, we found that inflammatory markers are altered by testosterone: High levels of the sum of neutrophils and lymphocytes combined with normal testosterone levels increased the overall mortality [ 21 ]. Unfortunately, we only have very few patients with testosterone levels available to study the influence of testosterone on low- and intermediate-risk PCa.…”

Section: Discussionmentioning

confidence: 99%

Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate

Taussky

Soulières

Chagnon

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

We analyzed the influence of the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) on the biochemical recurrence (BCR) in low-intermediate risk prostate cancer (PCa). A total of 604 patients treated with exclusive brachytherapy for low- and intermediate-risk cancers were included in this study. No patient received either androgen deprivation or brachytherapy as a boost. BCR was defined according to the Phoenix definition (nadir prostatic specific antigen (PSA) +2). The median follow-up was 60 months (IQR 44–48 months). An NLR > 3 was more frequent in statin users (p = 0.025), but not in diabetics (p = 0.079). In univariate analysis (UVA) and multivariate analysis (MVA), a NLR > 3 (MVA p = 0.03), as well as Cancer of the Prostate Risk Assessment (CAPRA) low- vs. intermediate-risk (MVA p = 0.04), were predictive of BCR. When combining the NLR score with the CAPRA risk group, CAPRA intermediate risk patients with an NLR ≤ 3 (n = 157) had the worst (p = 0.0276) BCR rates, with a 5-year recurrence-free survival (p = 0.004, Bonferroni correction for six comparisons p = 0.024). We were able to identify a subgroup of PCa patients with CAPRA intermediate-risk and an NLR ≤ 3 who had worse BCR. This is in contrast to most other cancers, which have a worse prognosis when the NLR is high.

show abstract

A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer

Abstract: A high WBC and lymphocyte count combined with normal testosterone levels increases the overall mortality of patients treated with radiotherapy for localized prostate cancer within the first 6-7 years post-treatment. Validation in larger cohorts is necessary.

Cited by 7 publications

References 25 publications

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer

Does testosterone mediate the relationship between vitamin D and prostate cancer progression? A systematic review and meta-analysis

Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate

Contact Info

Product

Resources

About